



Bio-Analytical Method Validation: Concept, Regulatory Guidelines And Application.

¹Neha Vijaykumar Kamble*, ²Amit Jayaji Gatkal, ³Triveni Navnath Gore, ⁴Vijaya Uday Barge

¹ Student Department of Pharmaceutical Quality Assurance, Shankarao Ursal College of Pharmaceutical Science & Research Centre, Kharadi, Pune 411014

² Student Department of Pharmaceutical Quality Assurance, Shankarao Ursal College of Pharmaceutical Science & Research Centre, Kharadi, Pune 411014

³ Student Department of Pharmaceutical Quality Assurance, Shankarao Ursal College of Pharmaceutical Science & Research Centre, Kharadi, Pune 411014

⁴ Vice Principal & assistant Professor Department of Pharmaceutical Quality Assurance, Shankarao Ursal College of Pharmaceutical Science & Research Centre, Kharadi, Pune 411014

Abstract

Bioanalytical method validation is an important process used to ensure that analytical methods provide reliable and accurate results for the determination of drugs and their metabolites in biological samples such as plasma, serum, blood, and urine. The development of a bioanalytical method involves selecting appropriate analytical techniques, optimizing sample preparation procedures, and establishing suitable chromatographic conditions. Common extraction techniques include protein precipitation, liquid-liquid extraction, and solid-phase extraction to improve analyte recovery and reduce matrix interference. Method validation evaluates key parameters such as accuracy, precision, selectivity, linearity, recovery, limit of detection, limit of quantification, and stability. These parameters confirm that the method is consistent, reproducible, and suitable for routine analysis. Bioanalytical methods play a crucial role in pharmacokinetic studies, drug discovery, and clinical research. Proper validation ensures the quality and reliability of analytical data and supports regulatory requirements in pharmaceutical development.

Key Words: Bioanalysis, Plasma, Validation, Chromatography, Precision, Selectivity, Drug Discovery, Stability, Pharmacokinetics

Introduction

Bioanalytical Method Validation (BMV) refers to the systematic process used to confirm that an analytical method is reliable and appropriate for measuring chemical compounds in biological samples. A bioanalytical method typically includes procedures for the collection, processing, storage, and analysis of biological matrices such as blood, plasma, serum, or urine. Validation ensures that the method consistently produces accurate and reproducible results for the intended biomedical application. This process involves performing a series of carefully designed experiments to verify the method's performance and reliability. An essential part of validation is the evaluation of analyte stability in biological samples obtained during clinical studies, along with the stability of important assay components such as reagents and analyte stock solutions. By demonstrating that the analytical method can reliably quantify analytes within complex biological matrices, bioanalytical method validation helps

ensure the quality and credibility of data generated in pharmaceutical and clinical research. ⁽¹⁾

Bioanalytical Method Validation (BMV) plays a crucial role in pharmaceutical research by ensuring that analytical methods used to measure drugs and their metabolites in biological samples are dependable and consistent. It is an essential requirement not only for regulatory submissions to agencies such as the U.S. Food and Drug Administration but also for maintaining the quality of scientific data generated during the drug discovery and development process ⁽⁴⁾

Analytical method validation plays a crucial role in ensuring the reliability and quality of data generated during bioanalytical studies. Important validation parameters include selectivity, sensitivity, calibration model, accuracy, precision, stability, recovery, linearity, limit of detection (LOD), lower limit of quantification (LLOQ), reproducibility, and ruggedness. Evaluation of these parameters confirms that the analytical method can consistently generate accurate and precise results for the intended purpose. ⁽¹⁰⁾

Validated bioanalytical methods are widely applied in quality control laboratories to assess essential attributes of pharmaceutical products such as identity, purity, potency, and overall quality, as well as to support bioavailability studies. When analytical testing is conducted across multiple laboratories, it becomes necessary to validate the method at each site to maintain consistency and reliability of results. Adequate validation data across laboratories helps ensure inter-laboratory comparability and strengthens confidence in the generated data. Therefore, the development and validation of robust bioanalytical methods are fundamental for producing reliable and scientifically interpretable analytical outcomes. ⁽³⁾

Why validate Bioanalytical method

The validation of a bioanalytical procedure is carried out to confirm that the analytical method performs consistently and produces trustworthy results. By evaluating the method's performance, researchers can establish confidence in the data generated during analysis. Validation is particularly important when bioanalytical results are intended to support the approval of a new drug or the modification of an existing pharmaceutical formulation. However, validation is not a one-time activity; after the initial validation process, the method must be continuously monitored during routine use to ensure that it maintains the same level of reliability and performance over time. This process involves systematic laboratory studies that document the method's characteristics and verify that it remains appropriate for its intended analytical purpose. ⁽¹¹⁾

Need of bioanalytical method validation

Properly characterized and fully validated bioanalytical methods are critical to obtaining accurate and reliable results. Such validation ensures that the data produced can be confidently interpreted and used for scientific or regulatory purposes, providing a foundation for meaningful conclusions in biomedical research.

Bioanalytical techniques are continuously evolving, reflecting ongoing advancements in technology. These improvements contribute to increased sensitivity, precision, and overall performance, keeping bioanalytical methods at the forefront of scientific innovation.

Each bioanalytical method has unique characteristics that can vary depending on the analyte being measured. As a result, specific validation criteria often need to be established for individual analytes to ensure that the method is appropriately tailored and produces accurate results for its intended application.

The selection of an appropriate bioanalytical technique is also influenced by the overall objectives of a study. In cases where sample analysis is performed at multiple laboratories, it is necessary to validate the method at each site independently. Providing thorough validation documentation for each location ensures inter-laboratory consistency and reliability of the generated data. ⁽¹⁶⁾

Requirements

- 1) Authenticated source for Biological Matrix.
- 2) Reference or working Standards.
- 3) Solvents and Chemicals.
- 4) Chromatographic Devices- Instruments, Columns.
- 5) Well trained Man Power
- 6) Literature.

Method validation

Method validation is the procedure used to confirm that an analytical method consistently meets or surpasses the required standards outlined in regulatory or scientific guidelines. This process involves conducting systematic laboratory studies to document that the method's performance characteristics—such as accuracy, precision, and reliability—are appropriate for its intended use. The credibility and acceptability of the analytical data are directly dependent on the rigor and criteria applied during the validation process. ⁽³⁾

1 Method development steps

- 2 Literature search for drugs
- 3 Physicochemical properties of the compound
- 4 Dose and Cmax of the compound
- 5 Selection of the chromatographic device
- 6 Reference standard preparation
- 7 Tuning of the compound
- 8 Optimization of chromatographic parameters
- 9 Optimization of extraction procedure
- 10 Sample storage

1.1 Literature search for drugs

A thorough review of the literature was conducted using scientific databases like PubMed, Google Scholar, and ScienceDirect to gather existing information on the drug and its analytical methods. This review provided insights into the physicochemical characteristics of the drug, the various analytical techniques available, and the current bioanalytical approaches used for its study.

1.2 Physicochemical properties of the compound

- a) Solubility
- b) pKa
- c) molecular weight
- d) molarity
- e) pH
- f) Log P

1.3 Dose and Cmax of the compound

- a) These two are required to find out the required LLOQ level and to fix the required Linearity range.
- b) As per regulatory guidelines
- c) LLOQ should be 5 half-life of the Cmax
- d) ULOQ should be 2 – 2.5 times of the Cmax

These data are useful for determining the suitable concentration range and sensitivity required during bioanalytical method validation. ⁽¹⁾

1.4 Selection of chromatographic device

- Selection of Chromatographic device is depending on the required sensitivity.
- Sensitivity ranged from sub pg/mL to $\mu\text{g/mL}$ level

1.5 Selection of Internal Standard

Internal standard should preferably labelled compound if not Structurally similar or pKa similar

1.6 Tuning of the compound

Source dependent Parameters-Curtain gas, nebulizing gas, Sheet gas, Source Voltage etc Compound Potential, Dependent Parameter-Declustering entrance potential, collision Energy, Exit Potential etc.

1.7 Optimization of chromatographic parameters

Mobile Phase, Mobile Phase Ratio, Column, Flow rate, Temperature, Injection volume, Carry Over

Optimization of mobile phase pH




Figure 1: It is the representation of graph between Retention vs PH for a hypothetical acid (a) and base(b)

Optimization of mobile phase pH




Figure 2: Representation of graph between Time (min) vs basic analytical

1.8 Optimization of extraction procedure

- 1) Liquid – liquid extraction
- 2) Solid phase extraction
- 3) Protein precipitation

1.8.1 Liquid–Liquid Extraction

Liquid–Liquid Extraction (LLE), also known as solvent extraction, is a widely used sample preparation technique in bioanalysis, typically performed before analytical methods such as chromatography or electrophoresis. In this method, analytes are transferred from an aqueous sample into an organic solvent that is immiscible with water. The extraction process relies on the distribution, or partition, coefficient of the analyte between the two liquid phases. Passive diffusion across the liquid–liquid interface allows the analyte to move from one phase to the other. After thorough mixing, the two solvents separate into distinct layers according to their densities, with the lighter solvent forming the upper layer.

The distribution of analytes between these layers depends largely on their solubility and polarity; hydrophilic compounds tend to remain in the aqueous phase, while hydrophobic compounds preferentially partition into the organic solvent. Once separated, the phases allow for isolation and concentration of the target analyte. Often, the organic layer is evaporated and then reconstituted with the mobile phase before further analysis. LLE is primarily employed to separate analytes from complex matrices, enhance detection, and prepare samples for subsequent analytical procedures. Although it is an effective technique, traditional LLE can be time-consuming and require large volumes of solvents, prompting modern research to explore miniaturized and more environmentally friendly extraction methods. ⁽⁶⁾




Figure 3: Liquid-Liquid Extraction

1.8.2 Solid phase extraction

Solid-Phase Extraction (SPE) is a widely used sample preparation technique that employs a solid adsorbent, typically packed in a cartridge or disc, to isolate target analytes from complex samples. During the process, the sample is slowly passed through the SPE material, allowing the analyte and some matrix components to be retained. A wash solvent can then selectively remove unwanted substances while keeping the analyte bound to the sorbent, effectively separating it from interferences and producing a cleaner sample for analysis. SPE works on the principle of partitioning between the liquid sample and solid sorbent, which improves sensitivity, reduces contaminants, and eliminates particle debris.

Cartridges generally contain 0.1–0.5 g of sorbent, such as C18 silica, packed between fritted discs to ensure smooth liquid flow. After washing away interferences, the analyte is eluted with an appropriate solvent and can be analysed directly or evaporated and reconstituted. SPE is compatible with a wide range of sample types, including urine, blood, tissues, soil, and beverages, with the analyte's affinity for the stationary phase determining how efficiently it is retained and eluted. Modern SPE cartridges are small, inert plastic tubes filled with reversed-phase or ion-exchange sorbents, making the technique highly efficient, automatable, and reproducible, and a preferred method for preparing clean samples prior to HPLC or other analytical techniques. ^(2,6)





Figure 4: Solid Phase Extraction



1.8.3 Protein Precipitation

Protein precipitation is a widely used technique to recover biomolecules, particularly proteins, from biological samples such as plasma or blood, and it is most effective when the analyte concentration is high. The process is typically induced by adding miscible organic solvents like methanol, acetonitrile, acetone, or ethanol, salts such as aluminium chloride, metal ions like zinc sulphate or by adjusting the pH using acids such as trichloroacetic, perchloric, metaphosphoric, or tungstic acid. This method can efficiently extract both hydrophilic and hydrophobic molecules, although in some cases, techniques like liquid-liquid extraction (LLE) or solid-phase extraction (SPE) may be employed to improve extraction efficiency for certain drugs or metabolites. Protein precipitation also helps remove matrix interferences, providing a cleaner sample for analysis. Typically, the sample is mixed with a precipitating agent in a ratio of one part sample to three or four parts agents, followed by vortex mixing and centrifugation. The resulting protein pellet is discarded, leaving the analyte in the supernatant, which can be analysed directly or, for quantitative purposes, evaporated and reconstituted in a suitable solvent. The overall success of protein precipitation depends on the solubility of the analyte in the selected precipitation solvent. ^(2,6)

1.8.4 Solid-phase microextraction

Solid Phase Microextraction (SPME), introduced in 1989, is a widely recognized solvent-free extraction technique, particularly for gas chromatography (GC). It offers a simple and automated approach for both environmental and bioanalytical applications. The method employs a fused silica fibre coated with a stationary phase, which is exposed either directly to the sample or to the headspace for volatile compounds. Key factors affecting extraction efficiency include temperature, pH, salt content, stirring, equilibrium, and contact time. The fibre serves as a single-phase system, enabling simultaneous

sampling, extraction, concentration, and direct transfer to analytical instruments such as GC, GC/MS, or even HPLC and HPLC-MS for thermally labile or weakly volatile compounds. SPME is cost- and time-efficient due to its simple syringe-like device with a retractable fibre, and it is particularly useful for complex matrices. The technique overcomes limitations of traditional methods like LLE and SPE, with successful extraction relying on the careful selection of the stationary phase to allow optimal analyte adsorption and desorption. ⁽⁶⁾

2 Types of Method Validation

1. Full validation
2. Partial validation
3. Cross validation

2.1 Full Validation

When developing and implementing a bioanalytical method for a new drug, full validation is essential to ensure accuracy, precision, and reliability. If an existing assay is modified to include the measurement of metabolites, then comprehensive validation must be conducted for all analytes being quantified, not just the newly added ones. ⁽¹⁹⁾

2.2 Partial validation

Partial validation applies to modifications of already validated bioanalytical methods and does not always require a full revalidation. The scope of partial validation can vary—from evaluating just one aspect, such as assay accuracy and precision, to performing an assessment that is almost equivalent to a full validation. Common examples of changes that may require partial validation include transferring the method between laboratories or analysts, switching instruments or software platforms, changing the species of the biological matrix (e.g., from rat plasma to mouse plasma), altering the matrix within the same species (e.g., human plasma to human urine), modifying the analytical approach (such as a different detection system), or adjusting sample processing procedures. ⁽⁶⁾

2.3 Cross validation

When multiple bioanalytical methods are used to produce research data or to compare results across different studies, cross-validation involves evaluating and comparing the validation parameters of these methods. One scenario is when a newly developed bioanalytical technique serves as the comparator while an established, validated method acts as the reference. This situation provides an example of cross-validation, and it is important that both methods are applied during the comparison to ensure reliable and consistent results. ⁽⁵⁾

3. Current validation practice on bioanalytical method validation

1. Accuracy
2. Precision
3. Linearity
4. Selectivity & Specificity
5. Limit of detection
6. Limit of quantitation
7. Standard curve (calibration curve)
8. Recovery
9. Stability
10. Ruggedness (Robustness)

3.1 Accuracy

Accuracy measures how closely a detected analyte concentration matches its nominal or true value, usually expressed as percentage relative error (%RE). It is calculated by comparing measured and actual concentrations of QC samples at low, medium, and high levels, both within a single day and across multiple days. Accuracy can be within-day (intra-assay) or between-day (inter-assay), typically requiring at least three runs. QC sample accuracy should not deviate more than $\pm 15\%$ from the true value, except at the LLOQ, where $\pm 20\%$ is allowed. Each QC level should be assessed using at least five replicate measurements. ^(7,14)

3.2 Precision

Precision refers to the consistency or reproducibility of measured analyte concentrations and is usually expressed as the coefficient of variation (%CV) or relative standard deviation (%RSD). It is assessed by repeated measurements of homogeneous samples and can be classified as within-day (intra-assay) precision, reflecting repeatability during a single run; between-day precision, based on at least three separate assays; and inter-assay precision, which evaluates reproducibility over time and may account for variations in personnel, equipment, and reagents. For quality control (QC) samples, the variation in precision should not exceed $\pm 15\%$, except at the lower limit of quantification (LLOQ), where $\pm 20\%$ is acceptable. Precision is typically determined using a minimum of five replicate measurements at each QC concentration level. ^(3,15)

3.3 Linearity

Linearity is the ability of a bioanalytical method to produce results that are directly proportional to the concentration of an analyte within the range of the standard curve. The calibration curve should span at least the concentrations expected in the study samples, and if a single curve cannot cover the entire range, two calibration ranges may be validated. Extending the range unnecessarily can compromise the method's accuracy and precision. Linearity is most commonly assessed using correlation coefficients to evaluate the relationship between measured responses and analyte concentrations. ^(16,17)

3.4 Selectivity

Selectivity is defined as the ability of a bioanalytical method to accurately measure the analyte of interest and distinguish it from other components that may be present, such as metabolites, impurities, degradants, or matrix constituents. This definition, outlined in Conference Report II, closely aligns with the ICH definition but emphasizes the potential presence of metabolites, making it particularly relevant for bioanalytical applications. Method selectivity can be evaluated by demonstrating minimal or no response in blank matrices, with the Conference Report recommending analysis of at least six different blank sources—a practice now considered standard. However, some researchers have argued that this may miss rare interferences, suggesting evaluation of 10–20 blank sources. For highly specific detection methods, such as hyphenated mass spectrometry, even a single blank source may be sufficient to establish selectivity. ^(1,17)

3.5 Limit of detection

Quantification below the lower limit of quantification (LLOQ) is not considered acceptable, meaning that concentrations below this threshold can only be reported qualitatively or semi quantitatively. Nevertheless, determining the limit of detection (LOD) remains important. According to ICH guidelines, LOD is the lowest analyte concentration that can be detected but not precisely quantified, while Conference Report II defines it as the lowest concentration that can be reliably distinguished from background noise. Methods for estimating LOD are similar to those used for LLOQ, typically applying a signal-to-noise ratio or k-factor of at least three. When using a calibration curve to determine LOD, only calibrators within the LOD range should be included.

3.6 Limit of quantitation

The lower limit of quantification (LOQ) is a critical parameter in bioanalytical method development and validation, representing the lowest analyte concentration that can be reliably quantified with acceptable precision and accuracy. Typically, LOQ is determined using independent samples and assessed based on relative standard deviation (RSD) and bias, often with acceptance criteria of $\pm 20\%$ for both parameters. In chromatographic and other instrumental methods, LOQ can also be estimated using the signal-to-noise ratio (S/N), with a value of 10 or higher commonly required to ensure distinguishable and reproducible detection.

3.7 Standard curve (calibration curve)

Linearity describes the relationship between the concentration of an analyte and the corresponding measured response in an analytical method. ⁽¹⁷⁾

3.8 Recovery

Extraction efficiency in an analytical procedure is expressed as the percentage of a known amount of analyte successfully recovered through the method's sample preparation and processing steps. While complete recovery is not expected, the analyte's recovery should be consistent and reproducible. Recovery is typically assessed by comparing the measured concentrations from extracted samples to those from spiked control extracts at multiple levels, usually low, medium, and high, to ensure reliability across the concentration range.

3.9 Stability

3.9.1 Stability in Bioanalytical Method Validation

Stability refers to how well an analyte remains unchanged in a sample under specific conditions over time. Testing stability is essential to make sure that measurements are accurate and reliable. In practice, this is done by comparing quality control (QC) samples analysed before and after exposure to certain conditions. Usually, tests are performed at low and high concentrations with several replicates, and results are considered acceptable if the analyte stays within a defined range, often 90–110% of the original value. ⁽⁸⁾

3.9.2 Types of Stability

There are different types of stability tested in bioanalytical studies. Long-term stability checks whether the analyte stays stable during storage under expected conditions. Freeze/thaw stability evaluates whether repeated freezing and thawing affects the analyte. In-process stability looks at whether the analyte remains stable during sample preparation. Processed sample stability examines the analyte in prepared samples during analysis or short-term storage, such as in an autosampler or refrigerator. These studies ensure that the analyte can be reliably measured at every step of the analysis.

3.10 Ruggedness

Ruggedness refers to how resistant an analytical method is to small, deliberate changes in experimental conditions, such as slight variations in pH, mobile phase composition, temperature, or other routine laboratory factors. Evaluating ruggedness helps identify potential sources of variability that could affect method performance, ensuring that the results remain reliable under normal working conditions. While full method validation does not always require ruggedness testing, it is particularly useful during method development or pre validation to detect issues before they become problematic in formal validation studies. ^(1,3)

4 Bioanalysis in Drug Discovery and Development

Bioanalytical methods play a key role throughout the drug discovery and development lifecycle, from early discovery to clinical trials. The process of lead optimization, confirmation, and testing of new drug candidates involves multiple stages, broadly divided into discovery, lead optimization, preclinical development, and clinical trials (Phases I–IV). Each stage places unique demands on bioanalytical assays, and the use of sensitive, specific, and flexible techniques, such as LC/MS/MS, allows fast and reliable decision-making.

4.1 PK and Bioanalysis in Drug Discovery

During the drug discovery phase, full pharmacokinetic (PK) characterization is not always required. However, bioanalytical assessment of bioavailability, often combined with *in vitro* studies, helps determine whether a compound is suitable for further development. Analytical priorities at this stage include rapid pass/fail assessment of PK parameters, medium-sensitivity assays, minimal assay development, and high specificity for the compounds of interest. ⁽¹⁾

4.1.1 Phase I: First-in-Human Studies

In Phase I trials, the primary goal is to characterize the absorption and elimination phases of a drug and its metabolites. Accurate measurement of PK parameters such as area under the curve (AUC) and maximum concentration (C_{max}) is essential to determine the no-toxic-effect dose for first-in-human dosing. Assays must be highly sensitive to detect low doses and metabolites, handle small sample groups, and undergo full validation.

4.1.2 Phase IIa and IIb: Efficacy and Dose Optimization

Phase IIa focuses on proof-of-concept studies in small patient groups to assess efficacy and PK/PD relationships, guiding decisions for further clinical development. Phase IIb involves dose-ranging studies to identify effective doses. Analytical priorities include high-sensitivity assays, high specificity for the drug and its metabolites, and rapid sample turnaround.

4.1.3 Phase III: Long-Term Clinical Studies

Phase III trials involve large patient populations to demonstrate efficacy across diverse groups. Bioanalytical methods at this stage must be highly specific, robust against matrix variability, and capable of processing large volumes of samples efficiently. Assays are typically focused on a few key analytes, but must maintain precision, accuracy, and throughput to support large-scale data generation. ^(1,18)

Conclusion

Bioanalytical method development and validation play a vital role in ensuring the reliability and accuracy of analytical data obtained from biological samples. Proper validation confirms that analytical methods are suitable for measuring drugs and their metabolites with acceptable precision, accuracy, and sensitivity. Important validation parameters such as selectivity, linearity, recovery, stability, and ruggedness help demonstrate the consistency and robustness of the method. In addition, appropriate sample preparation techniques and optimized chromatographic conditions improve the efficiency of bioanalytical analysis. Validated methods are essential throughout drug discovery, pharmacokinetic studies, and clinical trials, as they support reliable decision-making and regulatory acceptance. Therefore, the development of robust and well-validated bioanalytical methods is fundamental for generating high-quality scientific data in pharmaceutical research.

References

- 1) Sankar, P. R., Geethika, A. S., Rachana, G., Babu, P. S. and Bhargavi, J. 2019. Bioanalytical Method Validation: A Comprehensive Review. *International Journal of Pharmaceutical Sciences Review and Research*, 56(1).
- 2) Bhadru, B., Anusha, G. and Keerthana, J.P., 2025. A comprehensive review on bioanalytical method development and validation for pharmaceuticals. *International Journal of Pharmaceutical Sciences and Research*, 16(9), pp.2494–2500
- 3) Sonawane, L.V., Poul, B.N., Usnale, S.V., Waghmare, P.V. and Surwase, L.H., 2014. Bioanalytical method validation and its pharmaceutical application – A review. *Pharmaceutica Analytica Acta*, 5(3), p.288.
- 4) Shah, V.P., 2007. The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation. *The AAPS Journal*, 9(1), E43–E47.
- 5) Buick, A.R., Doig, M.V., Jeal, S.C., Land, G.S. and McDowall, R.D., 1990. Method validation in the bioanalytical laboratory. *Journal of Pharmaceutical and Biomedical Analysis*, 8(8–12) .629–637.
- 6) Lohare, P.S., Deshpande, M.M. and Varungase, A.T., 2022. A review on sample preparation and extraction techniques of bioanalytical method development and validation. *International Journal of Research and Analytical Reviews (IJRAR)*, 9(2), p.312–321.
- 7) Peters, F.T. and Maurer, H.H., 2002. Review: *Bioanalytical method validation and its implications for forensic and clinical toxicology – a review*. *Accreditation and Quality Assurance*, 7(11), pp.441–449.
- 8) Somthane, P.N., Shaikh, I.A., Bavage, N.B., Gali, V. and Bavage, S.B., 2019. *Bioanalytical method validation and its pharmaceutical application – A review*. *World Journal of Pharmaceutical Research*, 8(9), pp.738–751.
- 9) International Organization for Standardization, 1994. *Accuracy (trueness and precision) of measurement methods and results: ISO 5725-1 to ISO 5725-3*. Geneva: International Organization for Standardization.
- 10) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 1994. *Validation of analytical methods: Definitions and terminology*. ICH Q2A. Geneva: ICH.
- 11) Shah, V.P., Midha, K.K., Findlay, J.W., Hill, H.M., Hulse, J.D., McGilveray, I.J., McKay, G., Miller, K.J., Patnaik, R.N., Powell, M.L., Tonelli, A., Viswanathan, C.T. and Yacobi, A., 2000. *Bioanalytical method validation: A revisit with a decade of progress*. *Pharmaceutical Research*, 17(12), pp.1551–1557.
- 12) U.S. Food and Drug Administration (FDA), 2018. *Bioanalytical method validation: Guidance for industry*. Silver Spring, MD: Center for Drug Evaluation and Research, Center for Veterinary Medicine.
- 13) Tarle, S.B., Aher, S.S., Zade, D.B. and Bachhav, R.S., 2024. *An approach to bioanalytical method development and validation: A review*. *International Journal of Pharmaceutical Sciences*, 2(7), pp.382–393.
- 14) Dadgar, D., Burnett, P.E., Choc, M.G., Gallicano, K. and Hooper, J.W., 1995. *Application issues in bioanalytical method validation, sample analysis and data reporting*. *Journal of Pharmaceutical and Biomedical Analysis*, 13(2), pp.89–97.
- 15) Karnes, H.T., Shiu, G. and Shah, V.P., 1991. *Validation of bioanalytical methods*. *Pharmaceutical Research*, 8(4), pp.421–426.
- 16) Yadav, A.K., Singh, S.K., Yashwant and Verma, S., 2012. *Bioanalytical method validation – How, how much and why: A research perspective*. *International Journal of Natural Product Science*, 1(3), p.123.
- 17) Rozet E1, Marini RD, Ziemons E, Boulanger B, Hubert P (2011) Advances in validation, risk and uncertainty assessment of bioanalytical methods. *J Pharm Biomed Anal* 55: 848-858.
- 18) Panda, S., Chavan, T. and Bhavsar, R., 2023. *Advances in dried blood spot sampling and bioanalytical method validation under ICH M10 guidelines: A comprehensive review*. *International Journal of Chemistry Research*, 7(2), pp.45–56.
- 19) Vinod P. Shah, 2007. *The history of bioanalytical method validation and regulation: Evolution of a guidance document on bioanalytical methods validation*. *The AAPS Journal*, 9(1), p.E43–E47.
- 20)